LMNB2 and lung adenocarcinoma: FANCE is reported to be a vital factor influencing the poor survival of FANCE-deficient cells among breast cancer cell lines [30], and upregulation of LMNB2 is associated with significantly poorer prognosis in lung adenocarcinoma patients [31].